As the primary urate-lowering therapy, xanthine oxidase inhibitors (XOIs) such as allopurinol (the preferred first-line agent) or febuxostat4 are strongly recommended for all patients, including those with moderate‐to‐severe chronic kidney disease (CKD)5. This evidence concerns the gene XDH and chronic kidney disease.